Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNAZ Phase IIa trial of felzartamab in IgA nephropathy
2020-005054-19Phase 2Completed
- Sponsor
- Human Immunology Biosciences
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of felzartamab in IgA nephropathy (IgAN) (4 arms), sponsored by Human Immunology Biosciences. Primary endpoint: Relative change in 24-hour UPCR at 9 months. Started Mar 2021; status: completed.
02
Drugs
felzartamab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2020-005054-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005054-19.